IFX levels can be affected by numerous factors, including disease burden, behavior, patient characteristics, and genotype; pharmacodynamics, kinetics, and drug interactions. For those with good therapeutic response, losing clinical effect with IFX over time is common, with annual risk for loss of response (LOR) between 3% and 13% per patient-year. 10, 11 This is due to a combination of secondary LOR 12 and discontinuation due to adverse immunogenic effects. 13 Dose escalation has been used as a strategy to improve outcomes and prolong response. [14] [15] [16] Commercialization and increasing availability of drug level/antibody assays allows for accurate dose adjustment in clinical practice. 17, 18 Therapeutic drug monitoring (TDM) can be cost effective 19 and offers clinical improvement. 20, 21 However, effect of TDM-guided dose escalation on endoscopic outcomes remains unclear, We retrospectively evaluated association of TDM-driven IFX dose escalation with subsequent endoscopic remission in active inflammatory bowel disease (IBD) and compared outcomes with patients who underwent dose escalation based on clinical decision making alone.
MATERIALS AND METHODS

Study Objectives
Firstly, we aimed to examine the association between TDM-driven dose optimization and endoscopic outcomes and to secondly evaluate the relationship between use of TDM and postadjustment IFX trough concentration or presence of antibodies to infliximab (ATI).
Study Design and Conduct
Data Collection
This was a retrospective observational cohort study. Adult patients (18-75 yrs) with established IBD attending Mount Sinai Hospital, Toronto, a tertiary IBD referral center, were included. Data from primary responders to IFX who underwent dose intensification (interval reduction, dose increase, or both) from 2008 to 2014 were reviewed. Clinical demographics were obtained through chart review and from a centralized database. Indication for dose adjustment in all cases included objective endoscopic disease activity (defined as Mayo score .1, Simple Endoscopic Score for Crohn's Disease [SES-CD] score .3, or Rutgeerts' score .i2) documented ,3 months before adjustment.
Patients were divided into 2 cohorts: TDM-based decision to dose adjust (TDM) and dose adjustment based on clinical data without TDM (non-TDM) (Fig. 1) . TDM was available at the center for the entire time frame studied. The indication for TDM was documented. The control group was from the same time period although use of TDM was noted to increase as time progressed, likely reflective of changing practices.
Demographics included age at diagnosis, age at first IFX infusion, use of concomitant azathioprine/methotrexate, diagnosis, patient weights at each infusion, length of follow-up, IFX start/discontinuation dates, dates of dose adjustment, and FIGURE 1. Cohort identification. Three hundred thirty three episodes of dose adjustments identified (2008) (2009) (2010) (2011) (2012) (2013) (2014) . Twenty-one had incomplete data or were lost to follow-up. One hundred forty-nine episodes were associated with knowledge of preadjustment IFX level; 163 were based on other clinical data. All included patients had baseline and postadjustment endoscopic evaluations.
laboratory parameters including C-reactive protein (CRP) and albumin. Disease duration, location, and behavior based on Montreal classification and smoking status were recorded. Exclusion criteria included patients without documented endoscopic activity ,3 months before adjustment, patients with isolated small bowel disease, patients receiving less than 3 doses of IFX or considered still in the induction phase, ,6 months of follow-up postadjustment, or definite infective etiology (e.g., Clostridium difficile colitis or other documented enteric infection) which could have accounted for endoscopic activity.
Serum IFX trough levels and ATI were measured using a previously described commercially available homogenous mobility shift assay (Prometheus Laboratories, San Diego, CA). 22 Assays were free of charge to patients and available as part of a research agreement with the institution. The lower limit of quantification for the presence of IFX was 0.98 mg/mL, and the upper limit of quantification was 34 mg/mL. For ATI, lower limit of quantification and upper limit of quantification corresponded to effective serum concentrations of 0.56 and 27 mg/mL (3.1 and 150 U/mL), respectively. 22 Timing of level procurement was at discretion of the treating physician. Results were considered a trough level if taken within 7 days of next scheduled infusion. Trough levels taken ,6 weeks before dose optimization were considered preoptimization levels. Levels taken to evaluate response within 3 months of dose optimization were considered postoptimization levels. Dose optimization was defined as minimum reduction in the interval of 2 weeks or increase in dose of minimum 2.5 mg/kg. Dose changes related to patient weight change were not included. Ongoing IFX or treatment change was recorded. Treatment change was defined as discontinuation, further optimization, switch to another agent, or surgery.
Outcomes evaluated are defined in Table 1 . Endoscopic activity was assessed before and after dose adjustment at median 3 months before and 6 months after adjustment. Clinical activity was recorded at the time of decision to dose optimize and median 6 months after dose adjustment, using physician assessment and Harvey-Bradshaw Index (CD) 23 or clinical Mayo score (UC) 24 where available. Hospitalizations, flares requiring treatment, steroid use, and surgery in 12 months after index dose adjustment were recorded.
The SES-CD, 25 or Rutgeerts' score, 26 where appropriate, was used to assess endoscopic activity in CD. Patients with SES-CD score .7 or Rutgeerts' score .i1 were considered endoscopically active. Mayo endoscopic subscores 27 were used to assess endoscopic activity in UC with Mayo $1 considered active. Mucosal healing was defined as Mayo endoscopic score ,1 for UC and SES-CD ,3 in Crohn's.
Statistical Methods
Spearman's correlations, chi square, and binary logistic regression were undertaken. For categorical data, Fisher's exact test determined significance and Kruskal-Wallis or Mann--Whitney U test compared continuous and ordinal variables between groups. Preference was given to exact/nonparametric analysis to avoid assumptions of distribution in collected data. Odds ratios and 95% confidence intervals (CIs) were computed. Drug levels before and after intervention were compared by Wilcoxon paired sample testing.
Kaplan-Meier curve and Cox regression analyses assessed survival differences between groups. Receiver operating characteristic curves determined IFX and ATI concentration thresholds best discriminating endoscopic remission, defined as Mayo score ,1 or SES-CD ,3. A multivariable logistic model assessed clinical and laboratory factors as independent predictors of endoscopic remission. Factors included in the modeling process were disease type (UC/CD), sex, age at diagnosis, age at collection, time since first IFX infusion, age at first IFX, immunemodulator use, TDM-based decision, postadjustment IFX concentration, and postadjustment ATI concentration.
Factors not significant at the 0.1 level were removed by backward elimination. Multivariable logistic model evaluated TDM-based decision, IFX concentration .4.5 mg/mL, and ATI concentration ,3.13 U/mL as independent predictors of endoscopic remission. Models were adjusted for multiple observations per subject, as a random effect. Statistical analysis was performed using SPSS v 18.0 (Chicago, IL). P value # 0.05 was deemed to be significant.
Ethical Considerations
All serum samples analyzed were obtained as part of clinical care. The study complied with International Conference on Harmonization-Good Clinical Practice and applicable regulatory requirements. Consent included use of data/serum for other medical purposes. The study was reviewed by local research ethics board.
RESULTS
Study Population
Three hundred twelve episodes of IFX dose optimization in patients with endoscopically active disease were identified (n ¼ 271 individuals). One hundred forty-nine (n ¼ 128) had a preceding TDM; 163 (n ¼ 143) did not (Fig. 1) . Mean age at diagnosis was 28.5 years. Forty-one percent of patients were receiving concomitant immunosuppression at the time of dose adjustment. Demographic information and sample characteristics 
Endoscopic and Clinical Outcomes
Sixty-three percent of TDM dose adjustments resulted in endoscopic remission as defined, compared with 48% non-TDM dose adjustments (P , 0.05; Fig. 2A ; Table 3 ). Median Mayo score in TDM group preadjustment was 2 ( Table 2 ) and postadjustment was 1 (Table 3) . Median SES-CD preadjustment was 14 ( Table 2 ) and postadjustment was 6 (Table 3) . When looking at the Mayo score as a categorical variable, there is a clear shift from Mayo 2 and 3 preadjustment to Mayo 0 and 1 postadjustment in both groups. A larger proportion of the TDM group had improvements in their Mayo score (90% Mayo 2/3 preadjustment reduced to 43% postadjustment in the non-TDM group, 94% Mayo 2/3 preadjustment reduced to 31% postadjustment in the TDM group; P , 0.05; see Table and (Table 2 ) and postadjustment was 6 (3-13) (Table 3) overall, and when looking at individual groups, the TDM group had lower median SES-CD postadjustment than the non-TDM group, P ¼ 0.054.
Sixty-nine percent of the TDM group had clinical response as defined, compared with 57% non-TDM (P , 0.01; Fig. 2B ; Table 3 ). The proportions in clinical remission were 52% (TDM) and 48% (non-TDM; P ¼ 0.2; Table 3 ), respectively.
Health Care Utilization Measures
The TDM cohort had fewer hospitalizations 12 months after adjustment (22% TDM versus 35% non-TDM group, P ¼ 0.025). The TDM group had fewer documented flares requiring clinic attendance and treatment change in the year postoptimization ([mean no. of flares per patient] 0.5 TDM group versus 0.95 non-TDM, P ¼ 0.02; Table 3 ).
There was a trend toward further dose optimization and higher surgery rates in the non-TDM group, although not significantly so (P ¼ 0.1 and P ¼ 0.2).
Ongoing IFX use at last follow-up was similar in both groups (64% versus 68%, P ¼ 0.5). Time to discontinuation of treatment occurred at a similar rate. Kaplan-Meier survival analysis showed that no significant difference was noted in time to IFX discontinuation between the TDM and non-TDM group (log rank 0.647, Breslow/Wilcoxon 0.72).
Adjustments Made
There was no significant difference in median interval reduction (reduction of 2 wks) or median dose increase undertaken (increase of 5 mg/kg); however, in the TDM group, patients more often had tandem dose increase and interval reduction (19% TDM group versus 8.3% non-TDM; P , 0.01). 
Disease Phenotype
Separate analyses comparing outcomes in UC and CD were undertaken. In the TDM group, patients with UC had higher rates of endoscopic healing (64% versus 46% CD) although not significant (P ¼ 0.06). There was no difference in hospitalizations or switching treatment between CD and UC. Patients with UC had an independently shorter time to optimization from first infusion compared with patients with CD, indicating earlier dose escalation (10 versus 20 mo, P , 0.0001).
Postadjustment Levels
Median IFX trough levels increased significantly after TDM-based adjustment (from 1.5 [pre] to 11 mg/mL [post]; P , 0.0001; Fig. 3A ). Available postadjustment levels were compared (total n ¼ 157, TDM group n ¼ 95, non-TDM group n ¼ 55; Table 1 ) and were significantly higher in the TDM group compared with the non-TDM group (6.5 mg/mL, P ¼ 0.015; Fig. 3B ). The presence of ATI was also lower in the TDM group (P ¼ 0.03).
Postadjustment IFX concentration .4.5 mg/mL (area under curve ¼ 0.8; 95% CI, 0.71-0.88; Fig. 4 ) with a sensitivity of 92.9% and specificity of 47% (Youden's index) and ATI concentration of ,3.3 U/mL (area under curve ¼ 0.70; 95% CI, 0.63-0.81) with a sensitivity of 70.1% and a specificity of 34% (Youden's index) were associated with endoscopic remission.
Variables previously associated with endoscopic remission were compared between groups, including age, sex, disease phenotype, disease duration, treatment duration, and concomitant immunomodulation, none of which proved significant. Univariate analyses demonstrated significant associations between being in the TDM group, the presence of ATI and IFX concentration, and the presence of endoscopic remission (P , 0.01, P ¼ 0.03, P ¼ 0.009, respectively).
For the multivariable logistic model evaluating presence in the TDM group, postadjustment IFX, and postadjustment ATI as independent predictors of endoscopic remission, there were 155 patients with a complete set of IFX, ATI, and endoscopy on 2 consecutive time points. Multivariable analysis showed postadjustment IFX concentration (odds ratio 1.2 [95% CI, 1.1-1.3]; P , 0.0001) remained an independent predictor of endoscopic remission.
DISCUSSION
This study compared outcomes of IFX dose adjustment in 2 decision-based groups: using TDM and clinical data or using clinical data alone. All patients had endoscopic disease activity documented before adjustment. To our knowledge, this is the FIGURE 3. Postadjustment trough levels in TDM versus non-TDM groups. A, Median IFX trough levels improved in the TDM group after adjustment from 1.5 to 11 mg/mL (P , 0.001). B, Median IFX trough levels after adjustment were lower in the non-TDM group (6.5 mg/mL, P , 0.01; total population with postadjustment level n ¼ 109, TDM n ¼ 67, non-TDM group n ¼ 42). largest evaluation of the relationship between TDM-based decisions around dosing and endoscopic outcomes that has been reported.
Our results are consistent with published data, suggesting that TDM-guided dose adjustment improves clinical outcomes. Yanai et al 20 assessed adalimumab and IFX levels to guide decision making to switch treatment or escalate dose. Their findings suggested that TDM can guide decision making in the majority of those with clinically suspected inflammatory LOR to therapy. Definitions for clinical worsening were not stringent, and only a small proportion of UC patients were included. In our study, only IFX was examined, and we focused on effects of endoscopic appearance and health care utilization. In addition, the comparison of outcomes with a large "control" cohort who underwent dose adjustment without previous TDM is not previously reported in this population.
Our data confirm the strong correlation between IFX trough concentration and endoscopic remission with a postadjustment trough .4.5 mg/mL discriminating for endoscopic remission. This value is comparable with levels noted by Vande Casteele et al 21 for laboratory remission in the Trough level Adapted infliXImab Treatment (TAXIT) trial, defined as CRP ,5. Confirmatory studies of threshold for endoscopic remission with prospectively acquired data are required for validity, but more recent real-world data looking at patients on both IFX and adalimumab also suggest that early use of TDM is associated with mucosal healing albeit in smaller cohorts than the one presented here. 28, 29 This study provides insight into the relationship between IFX levels, ATI, and endoscopic disease activity. We observed that changes in IFX levels after treatment intensification but not in ATI detection are associated with positive endoscopic outcomes. This could be due to the small numbers noted with ATI but is consistent with the findings of Steenholdt et al 30 during treatment intensification after therapeutic failure in CD.
Interestingly, we observed no difference in time on IFX between groups, but time to an alternative decision such as switch, stop or surgery was shorter in the TDM group. We observed different timelines to dose adjustment in UC and CD, with patients with UC requiring dose adjustment much earlier. O'Donnell et al 31 have previously shown that higher rates of dose optimization are required in UC to retain IFX response. This need for more aggressive dosing in UC has been noted in acute severe UC. Dose acceleration may reduce early colectomy, and there are data showing that higher IFX levels are associated with reduced colectomy in that setting. [32] [33] [34] Although patients with UC require dose adjustment sooner, analysis of UC and CD separately did not significantly alter our receiver operating characteristic associations of IFX levels with endoscopic remission.
Other important applications of TDM are evolving, including preemptive rather than reactive dose optimization. This strategy could improve therapeutic efficacy, reduce ATI, and decrease cost. 19, 35 TAXIT, in which levels after adjustment were prospectively evaluated during maintenance therapy in stable patients, found that better clinical outcomes were achieved when a threshold IFX trough concentration $3 mg/mL was targeted, and patients with IFX trough concentration .7 mg/mL could be safely de-escalated, resulting in lower costs without affecting clinical remission. 21 The cost savings of this strategy have yet to be examined in a North American cohort. In this cohort, assays were provided as part of a research agreement, so cost benefit was not specifically studied here. It could be surmised, however, that appropriate use of TDM should offset the health care costs of increasing dose/reducing intervals of treatment through reduced hospitalization and health care utilization in this setting.
We looked at effects of dose escalation; however, we acknowledge that this is not always the optimal choice. Various assay-based algorithms on managing secondary LOR have been developed. 19 Using these, for example, patients with subtherapeutic IFX concentrations without ATI may benefit from dose intensification, whereas those who are ATI negative with adequate IFX troughs may benefit from switching "out of class." 34 We acknowledge several further limitations. Firstly, the retrospective observational design precludes assumptions regarding causation. Decision to perform a trough level or dose optimization was at the treating physician's discretion rather than a protocol-led approach which may carry inherent selection bias, as treatment strategies changed over time and with increasing knowledge. Objective inclusion criteria and use of defined clinical endpoints were used to reduce such bias. This study is therefore more reflective of "real" practice compared with prospective data where dose optimization was performed in patients on stable doses with minimal disease activity. 21 Secondly, there may be population bias, as patients were identified by dose change, thus limiting examination of patients who had a level and no dose change. How these patients benefit is still to be answered, but we hypothesize that one reason the TDM group has better outcomes is because those patients who would not benefit from dose increases (those with adequate levels or high antibody titers) are not included in this cohort, whereas they make up a proportion of the non-TDM group resulting in increased exposure to drug in patients who will not gain clinically and added unnecessary health care cost.
Finally, IFX and ATI thresholds identified were not independently confirmed in a separate population. This is an important limitation that should be addressed in further prospective studies. Notwithstanding, these data highlight the values of performing TDM and the specific association of TDM-based dose optimization with endoscopic outcome which hitherto had not been evaluated.
In summary, we found that TDM-guided dose escalation is associated with higher postadjustment levels, and in turn, higher endoscopic remission rates and fewer relapses. These data support the accumulating literature advocating TDM use to aid decision making in IBD.
